Phaseline

Companies › Yarrow Bioscience

Yarrow Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YB-101–Phase 2Graves' DiseaseDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07682896YB-101Phase 2Graves' DiseaseMetabolic and endocrineDec 2027

From the company's SEC filings

Cash and short-term investments of $23m on 2026-06-30; operating cash outflow about $12m a year; runway about 22 months at that burn, to May 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SAb Biotherapeutics Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Portal Therapeutics Op-T

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.